Phio Pharmaceuticals

#10252

Rank

$14.46M

Marketcap

United States

Country

Leadership team

Ms. Caitlin Kontulis (VP of Fin. & Admin. and Sec.)

Mr. Robert J. Bitterman (Interim Exec. Chairman)

Dr. Geert Cauwenbergh Dr., Med.Sc., Ph.D. (Interim Principal Exec. & Financial Officer and Director)

Products/ Services

Biotechnology, Health Care, Medical

Headquarters

Worcester, Massachusetts, United States

Established

2011

Company Registration

SEC CIK number: 0001533040

Traded as

PHIO

Social Media

URL

https://www.phiopharma.com

Overview

Location

Recognition and Award

References

Summary

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

History

Phio Pharmaceuticals was founded in 2015 by a team of pioneering scientists, industry experts and top biotechnology investors. Our mission is to develop and deliver innovative immunotherapies to fundamentally change the way patients with cancer are treated. We have built our company on a commitment to innovation, collaboration, and a patient-driven mission to treat cancer.

Mission

Our mission is to deliver best-in-class, smart and safe immune-therapeutic solutions to meet the needs of cancer patients and physicians world-wide.

Vision

Our vision is to develop life-transforming immunotherapies and make them available to patients in need.

Key Team

Ms. Caitlin Kontulis (VP of Fin. & Admin. and Sec.)

Mr. Robert J. Bitterman (Interim Exec. Chairman)

Dr. Geert Cauwenbergh Dr., Med.Sc., Ph.D. (Interim Principal Exec. & Financial Officer and Director)

Recognition and Awards

Phio Pharmaceuticals has received numerous awards and recognitions, including the Digital Transformation of the Year in the 2021 PharmaTech awards, the Most Innovative Immunotherapy Company at the World Immunotherapy conference, and the Future Healthcare Innovator Award at the World Health Innovation Summit.